Download Files:
Zaprinast
SKU
HY-B1816-10 mg
Category Reference compound
Tags GPCR/G Protein;Metabolic Enzyme/Protease, GPR35 ;Phosphodiesterase (PDE), Neurological Disease; Cardiovascular Disease; Endocrinology
$42 – $340
Products Details
Product Description
– Zaprinast (M&B 22948) is a selective inhibitor of cGMP-selective Phosphodiesterase (PDE5). Zaprinast causes a significant increase in cGMP levels in myocytes. Zaprinast is a G protein-coupled receptor 35 (GPR35) agonist which activates rat GPR35 strongly and activates human GPR35 moderately. Zaprinast reduces vessel remodeling through antiproliferative and proapoptotic effects[1][2][3].
Web ID
– HY-B1816
Storage Temperature
– -20°C (Powder, protect from light, stored under nitrogen)
Shipping
– Blue Ice
Applications
– COVID-19-immunoregulation
Molecular Formula
– C13H13N5O2
References
– [1]Nina Divorty, et al. Agonist-induced phosphorylation of orthologues of the orphan receptor GPR35 functions as an activation sensor. J Biol Chem. 2022 Mar;298(3):101655.|[2]Furuzan Akar, et al. Zaprinast and rolipram enhances spatial and emotional memory in the elevated plus maze and passive avoidance tests and diminishes exploratory activity in naive mice. Med Sci Monit Basic Res. 2014 Jul 24:20:105-11.|[3]Choi SH , et al. Zaprinast, an inhibitor of cGMP-selective phosphodiesterases, enhances the secretion of TNF-alpha and IL-1beta and the expression of iNOS and MHC class II molecules in rat microglial cells. J Neurosci Res. 2002 Feb 1;67(3):411-21.|[4]Taniguchi Y, et al. Zaprinast, a well-known cyclic guanosine monophosphate-specific phosphodiesterase inhibitor, is an agonist for GPR35. FEBS Lett. 2006 Sep 18;580(21):5003-8. Epub 2006 Aug 17.|[5]Keswani AN , et al The cyclic GMP modulators YC-1 and zaprinast reduce vessel remodeling through antiproliferative and proapoptotic effects. J Cardiovasc Pharmacol Ther. 2009 Jun;14(2):116-24.
CAS Number
– 37762-06-4
Molecular Weight
– 271.27
Compound Purity
– 99.95
SMILES
– O=C1C(N=NN2)=C2N=C(C3=CC=CC=C3OCCC)N1
Clinical Information
– No Development Reported
Research Area
– Neurological Disease; Cardiovascular Disease; Endocrinology
Solubility
– DMSO : 62.5 mg/mL (ultrasonic)
Target
– GPR35 ;Phosphodiesterase (PDE)
Isoform
– PDE5
Pathway
– GPCR/G Protein;Metabolic Enzyme/Protease
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.